News archive
Showing 768 results
April 2026
-
Media Release
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded… -
Media Release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,…
March 2026
-
Story Hope
The Future of Treating Autoimmune Diseases: Science, Tech, & Patients Driving Progress
Today, 1 in 10 people in the United States have an autoimmune disease. Scientific innovations are opening pathways to help more patients.
-
Media Release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1… -
Story Education and Awareness
Susan’s Story: I Never Imagined I’d Be Someone Who Had a Heart Attack
For Susan, having two heart attacks in the span of a year was a wake-up call. It led her to be tested for high lipoprotein (a), a hidden heart disease risk factor that approximately 1 in 5 Americans may have1.
-
Media Release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx® data build on extensive body of… -
Media Release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL‑17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty,… -
Story Education and Awareness
"Could We End Preventable Heart Disease in Our Lifetime?" Novartis leaders explore at TIME100 Health event
If we look beyond the latest health trends, a healthy heart is the true key to more life in every year. Novartis US President Victor Bultó explains why preventing cardiovascular disease is the longevity breakthrough that matters.
-
Story Education and Awareness
Five Questions with Des Creary, Novartis US Chief Customer Engagement Officer
In this interview, Des shares his perspective on why it is important we work to better support healthcare practitioners who help treat our patients, and why real innovation resides in people as much as it resides in products.
February 2026
-
Media Release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands… -
Story Discovery
The Power of PRECISION: Using AI to Navigate the Future of Prostate Cancer Care
How a Novartis data platform is turning real-world evidence into actionable insights for urologists and oncologists.
-
Media Release
New real‑world data reinforce earlier use of Pluvicto® before chemotherapy in metastatic castration-resistant prostate cancer
In the real-world, Pluvicto® showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC Real‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI…